GlassScriptPhysician profile
Amy E Gershater
NPI 1558601146
$1,669.96
in general payments reported to CMS, 2019-2025
12 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $408 · 2023: $404 · 2024: $348 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.11 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $449.40 | 2021-2023 | Invega Sustenna |
| Indivior INC. | $187.16 | 2023-2025 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $130.63 | 2021-2023 | Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $101.46 | 2021-2024 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $78.10 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $68.56 | 2022-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.65 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $61.83 | 2023-2024 | Auvelity |
| Biogen, INC. | $28.30 | 2024 | |
| Sunovion Pharmaceuticals INC. | $27.89 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.87 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Gershater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.